Computer Aided Detection Market Size, Share & Trends Analysis Report By Application (Breast Cancer, Lung Cancer, Colon Cancer, Liver Cancer, Neurological Indications), By Indication, By Region And Segment Forecasts, 2023 - 2030

Report Overview

The global computer-aided detection market size was valued at USD 818.5 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2030. Increasing cancer prevalence and raising awareness in the population for regular health check-ups are the most significant drivers of the global computer-aided detection (CAD) industry. The deaths due to cancer have led the governments to take various awareness initiatives along with the key industry contributors to come up with breakthrough imaging technologies. According to an article published by the American Cancer Society (ACS), 43,250 women deaths from breast cancer were estimated in 2022, with 287,850 new instances of invasive breast cancer. Women aged 50 and over accounted for 83% of new cases of invasive breast cancer and 91% of all breast cancer-related deaths. The applications of CAD in cancer detection and treatment act as a driving force for the market's growth. 

Over the last two decades, the diagnostic cancer imaging field has witnessed remarkable evolution and has affected cancer research and clinical management. Tobacco smoking is one of the most common causes of lung cancer and is a leading cause of death in the U.S. Moreover, the number of deaths in women from smoking is expected to increase rapidly over the forecast period.

According to ACS, cancer accounted for 1 in 5 deaths in the U.S. Among these, smoking is responsible for 30% of all cancer fatalities and 20% of all cancer cases.

According to the World Health Organization (WHO) estimates, in 2022, cancer is the leading cause of death worldwide, resulting in approximately 10 million deaths in 2020, or nearly one in six deaths. The enhanced government initiatives to promote cancer awareness and treatment are anticipated to speed up the market's growth. For instance, the U.S. government relaunched the Cancer Moonshot in February 2022, aiming to cut the death rate from cancer by at least 50% over the following 25 years.

One noticeable trend is the rising use of AI and machine learning algorithms in CAD systems. These technologies have allowed CAD systems to detect anomalies more accurately and efficiently, improving diagnostic capabilities and lowering false-positive rates. In 2020, the endoscopic program ENDO-AID CAD, a cutting-edge platform driven by artificial intelligence (Al) for the colon, was released by Olympus Corporation, which provides a real-time presentation of automatically detected problematic lesions.

The spread of CAD into other medical specialties outside radiology is another noteworthy development. While CAD systems were primarily focused on mammography for the early identification of breast cancer, they have since expanded into fields like gastrointestinal imaging, cardiovascular imaging, and lung imaging. By enabling the detection of many diseases and ailments across multiple medical specialties, this growth has widened the applications of CAD.

Indication Insights

Based on indication, the market is segmented into X-ray imaging, computed tomography, ultrasound imaging, magnetic resonance imaging, nuclear medicing imaging, and others. The X-ray segment held the largest revenue share in 2022. Mammography technology dominated the market in 2022. This is attributed to the increasing incidence of cancer, which accounts for significant mortality and mortality.

Moreover, the X-ray segment is expected to grow significantly as it forms the basis for any imaging technique and has a significant market share. Moreover, extensive research has also been done to overcome the limitations of X-rays. In November 2021, Nanox, an Israeli imaging company, announced the completion of its merger with Zebra Medical Vision. The merger is expected to form next-generation AI-enabled medical software & hardware, thereby setting a new standard in the healthcare technology industry.

Application Insights

Based on application, the market is segmented into tuberculosis, breast cancer, lung cancer, colon/rectal cancer, prostate cancer, liver cancer, bone cancer, and neurobiological/musculoskeletal/ cardiovascular indications. The breast cancer segment dominated the market in 2022 with a market share of 67.1% owing to the increasing incidence rate of breast cancer globally, increasing awareness & initiatives, early detection, and improvements in available treatment. In 2020, 2.3 million women were diagnosed with breast cancer, with 685,000 deaths globally.

The lung cancer segment is expected to be the fastest-growing segment, with a CAGR of 8.2% over the forecast period from 2023 to 2030. According to the National Cancer Institute (NCI), in 2021, lung cancer is responsible for the highest number of cancer cases and deaths worldwide. It is estimated that there are approximately 2 million new cases and 1.8 million deaths attributed to lung cancer. Among both men and women, lung cancer ranks second most frequently diagnosed, following prostate cancer in men and breast cancer in women. The prevalence of lung cancer is escalating globally due to the enhanced availability of tobacco and increased industrialization in developing countries.

Regional Insights

In 2022, North America dominated the market and accounted for the largest revenue share of 45.9%. Wide use of CAD for cancer diagnosis, and the region's increased healthcare spending, are expected to fuel the expansion of the market. The American Cancer Society reports that, after heart disease, cancer remains the second most prevalent cause of death in the U.S. In 2020, there were 602,350 deaths due to cancer, among which 284,619 were females and 317,731 males.

Asia Pacific is expected to grow at the fastest CAGR of 7.4% during the forecast period. The high prevalence of cancer-related mortality is a key factor driving the demand for computer-aided cancer detection and diagnosis. As per the study published in the National Library of Medicine, the cancer incidence rate was 169.1 per 100,000 in Asia, which accounted for 49.3% of global cancer cases and breast (10.8%), lung (13.8%), and colorectal (10.6%) cancers were the most common cancers.

Key Companies & Market Share Insights

In order to improve their market position, the major players in the industry use various strategies, such as introducing new products and mergers, collaboration, partnerships, and acquisitions. Several market participants are now implementing demand-friendly strategic plans. For instance, in March 2022, an agreement was signed between EDDA Technology and the Society of Interventional Oncology (SIO) for the Ablation with Confirmation of Colorectal Liver Metastases Prospective Trial for Microwave Ablation as a Local Cure (ACCLAIM). In November 2021, Fujifilm announced the clinical trials of the REiLI Artificial Intelligence Platform created for the detection and diagnosis of intracranial hemorrhage and breast cancer. The following are some of the major participants in the global computer aided detection market:

• EDDA Technology, Inc.

• FUJIFILM Holdings Corporation

• Hologic, Inc.

• Koninklijke Philips N.V

• Siemens

• NANO-X IMAGING LTD.

• CANON MEDICAL SYSTEMS CORPORATION

• GENERAL ELECTRIC

• IBM

• Riverain Technologies

• iCAD, Inc.

• Median Technologies

• Hitachi Ltd

• Shimadzu Analytical (India) Pvt. Ltd

• Carestream Health

• ESAOTE SPA

• Narayana Hrudayalaya Ltd

• Karyopharm

Computer Aided Detection Market Report Scope

Global Computer Aided Detection Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. this study, Grand View Research has segmented the global computer aided detection market on the basis of application, indication and region:

• Application Outlook (Revenue in USD Million, 2018 - 2030)

  • Tuberculosis

  • Breast cancer

  • Lung cancer

  • Colon cancer

  • Prostate cancer

  • Liver cancer

  • Bone cancer

  • Neurological/Musculoskeletal/Cardiovascular indications

• Indication Outlook (Revenue in USD Million, 2018 - 2030)

  • X-Ray imaging

  • Computed tomography

  • Ultrasound imaging

  • Magnetic resonance

  • Nuclear medicing imaging

• Regional Outlook (Revenue in USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait